Clinical Trial Update: Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of vemurafenib and cobimetinib in high-risk differentiated thyroid carcinoma with BRAFV600E mutation; recruitm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Oncocytic Carcinoma of the Thyroid
• Papillary Thyroid Carcinoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma | Phase 2 | Status: RECRUITING